Uni-Bio and Beijing Sun-Novo to Co-Develop Diabetes Treatments

Uni-Bio Science of Hong Kong signed an agreement with Beijing Sun-Novo Pharma to co-develop multiple oral small molecule treatments for diabetes in China. Initially, the two companies will focus on developing acarbose-class tablets to treat type 2 diabetes, and the collaboration will continue to develop a portfolio of diabetes-aimed products. Beijing Sun-Novo will complete the chemistry, manufacturing and control processes along with the bioequivalence study of acarbose. Uni-Bio will apply for drug licenses from the CFDA and commercialize the product upon approval. More details.... Stock Symbol: (HK: 690) Share this with colleagues: // //